Cargando…

Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma

BACKGROUND: Medulloblastoma is the most common malignant pediatric brain tumor and group 3 subtype medulloblastoma (G3-MB) exhibits the worst prognosis. Super enhancers (SEs) are large clusters of enhancers that play important roles in cancer through transcriptional control of cell identity genes, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Meng, Han, Yujie, Wang, Chaochen, Kang, Wenfeng, Jiang, Wenyan, Zhang, Lei, Tang, Yujie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587669/ https://www.ncbi.nlm.nih.gov/pubmed/36273157 http://dx.doi.org/10.1186/s13046-022-02506-y

Ejemplares similares

Medulloblastoma under Siege: Genetic and Molecular Dissection Concerning Recent Advances in Therapeutic Strategies
por: Rawal, Zeal D, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

Hierarchy within the mammary STAT5-driven Wap super-enhancer
por: Shin, Ha Youn, et al.
Publicado: (2016)

Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma
por: Brun, Sonja N., et al.
Publicado: (2014)

Wnt activation as a therapeutic strategy in medulloblastoma
por: Manoranjan, Branavan, et al.
Publicado: (2020)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies
por: Shi, Yang, et al.
Publicado: (2022)

MEDB-87. Transcriptome-driven drug repurposing in group 3 medulloblastoma
por: Doss, David, et al.
Publicado: (2022)

The whole-genome landscape of medulloblastoma subtypes
por: Northcott, Paul A., et al.
Publicado: (2017)

MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA
por: Taban, Kübra, et al.
Publicado: (2020)

Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma
por: Yao, Yue‐Liang, et al.
Publicado: (2022)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
por: Chaturvedi, Nagendra K., et al.
Publicado: (2019)

Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1
por: Zhao, Yang, et al.
Publicado: (2020)

Subtypes of medulloblastoma have distinct developmental origins
por: Gibson, Paul, et al.
Publicado: (2010)

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)

MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)

A facile and effective strategy to develop a super-hydrophobic/super-oleophilic fiberglass filter membrane for efficient micron-scale water-in-oil emulsion separation
por: Zhou, Yujie, et al.
Publicado: (2022)

Polyamine Metabolism as a Therapeutic Target in Hedgehog-Driven Basal Cell Carcinoma and Medulloblastoma
por: Coni, Sonia, et al.
Publicado: (2019)

Characterization of a novel OTX2‐driven stem cell program in Group 3 and Group 4 medulloblastoma
por: Stromecki, Margaret, et al.
Publicado: (2018)

HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma
por: Bell, Jonathan B., et al.
Publicado: (2018)

The transcriptional landscape of Shh medulloblastoma
por: Skowron, Patryk, et al.
Publicado: (2021)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

Current Strategies for Management of Medulloblastoma
por: Prados, Michael D.
Publicado: (2023)

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma
por: Prince, Eric W., et al.
Publicado: (2016)

MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS
por: Pugh, Trevor J., et al.
Publicado: (2012)

Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes
por: Liang, Lisa, et al.
Publicado: (2015)

A transcriptome-based classifier to determine molecular subtypes in medulloblastoma
por: Rathi, Komal S., et al.
Publicado: (2020)

SuperTranscripts: a data driven reference for analysis and visualisation of transcriptomes
por: Davidson, Nadia M., et al.
Publicado: (2017)

Group-specific cellular metabolism in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

The oncogenic circular RNA circ_63706 is a potential therapeutic target in sonic hedgehog-subtype childhood medulloblastomas
por: Katsushima, Keisuke, et al.
Publicado: (2023)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma
por: Pritha, Ariana, et al.
Publicado: (2022)

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer
por: Kelly, Michael R., et al.
Publicado: (2022)

Erratum to: SuperTranscripts: a data driven reference for analysis and visualisation of transcriptomes
por: Davidson, Nadia M., et al.
Publicado: (2017)

Landscape and significance of human super enhancer-driven core transcription regulatory circuitry
por: Feng, Chenchen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b2dto115rt7in6br458721rou2